Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-42165279 in Healthy Japanese Men
NCT03564379Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-42165279 in anxiety disorders and major depressive disorder (MDD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events and Plasma Concentration of JNJ-42165279. Started Jun 2018; status: completed.
02
Drugs
JNJ-42165279
03
Conditions
anxiety disordersmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03564379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564379.